Treatment of colorectal cancer in older patients

Nature Reviews Gastroenterology and Hepatology

Volumn 9, Issue 12, 2012, Pages 716-725

  Audisio, Riccardo A ^a   Papamichael, Demetris ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b Cyprus Oncology Center   (Cyprus)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB;

ANASTOMOSIS LEAKAGE; ARTERY THROMBOSIS; BLEEDING; BLOOD TOXICITY; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COLON CANCER; COLON RESECTION; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; DISTANT METASTASIS; DRUG RESPONSE; EMERGENCY SURGERY; FISTULA; FRAIL ELDERLY; GERIATRIC ASSESSMENT; HUMAN; HYPERTENSION; INTERMETHOD COMPARISON; INTRAOPERATIVE RADIOTHERAPY; LAPAROSCOPIC SURGERY; LIFE EXPECTANCY; LIVER TOXICITY; METAL STENT; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MUCOSA INFLAMMATION; NEUTROPENIA; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; PROTEINURIA; QUALITY OF LIFE; RECTUM CANCER; RECTUM SURGERY; REVIEW; RISK ASSESSMENT; SELF EXPANDING STENT; SENSORY NEUROPATHY; SURGICAL APPROACH; SURGICAL MORTALITY; SURGICAL RISK; SYSTEMIC THERAPY; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM; VOMITING; WOUND HEALING IMPAIRMENT;

AGE FACTORS; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE MANAGEMENT; HUMANS; LIFE EXPECTANCY; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84870602575     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2012.196     Document Type: Review

References (100)

1. Ferlay, J., Parkin, D. M. & Steliarova-Foucher, E. Estimates of cancer incidence and mortality in Europe in 2008. Eur. J. Cancer 46, 765-781 (2010).
2. Pavlidis, T. E. et al. Safety of bowel resection for colorectal surgical emergency in the elderly. Colorectal Dis. 8, 657-662 (2006). (Pubitemid 44363588)
3. Heriot, A. G. et al. Prediction of postoperative mortality in elderly patients with colorectal cancer. Dis. Colon Rectum 49, 816-824 (2006). (Pubitemid 43846617)
4. National Health Service. NHS Bowel Cancer Screening Programme [online], http://www.cancerscreening.nhs.uk/bowel/index.html (2012).
5. Walter, L. C. & Covinsky, K. E. Cancer screening in elderly patients: A framework for individualized decision making. JAMA 285, 2750-2756 (2001). (Pubitemid 32525372)
6. Quaglia, A. et al. The cancer survival gap between elderly and middle-Aged patients in Europe is widening. Eur. J. Cancer 45, 1006-1016 (2009).
7. Lemmens, V. et al. Trends in colorectal cancer in the south of the Netherlands 1975-2007: Rectal cancer survival levels with colon cancer survival. Acta Oncol. 49, 784-796 (2010).
8. Rutten, H. et al. Survival of elderly rectal cancer patients not improved: Analysis of population based data on the impact of TME surgery. Eur. J. Cancer 43, 2295-2300 (2007). (Pubitemid 47539120)
9. van den Broek, C. B. et al. The survival gap between middle-Aged and elderly colon cancer patients. Time trends in treatment and survival. Eur. J. Surg. Oncol. 37, 904-912 (2011).
10. Aparicio, T. et al. Half of elderly patients routinely treated for colorectal cancer receive a sub-Standard treatment. Crit. Rev. Oncol. Hematol. 71, 249-257 (2009).
11. Townsley, C. A., Selby, R. & Siu, L. L. Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J. Clin. Oncol. 23, 3112-3124 (2005). (Pubitemid 46224135)
12. Zulman, D. M. et al. Examining the evidence: A systematic review of the inclusion and analysis of older adults in randomized controlled trials. J. Gen. Intern. Med. 26, 783-790 (2011).
13. Seymour, M. T. et al. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): An open-label, randomised factorial trial. Lancet 377, 1749-1759 (2011).
14. Fleming, F. J., Påhlman, L. & Monson, J. R. Neoadjuvant therapy in rectal cancer. Dis. Colon Rectum 54, 901-912 (2011).
15. Rutten, H. J., den Dulk, M., Lemmens, V. E., van de Velde, C. J. & Marijnen, C. A. Controversies of total mesorectal excision for rectal cancer in elderly patients. Lancet Oncol. 9, 494-501 (2008). (Pubitemid 351626863)
16. Kapiteijn, E., Putter, H. & van de Velde, C. J. Impact of the introduction and training of total mesorectal excision on recurrence and survival in rectal cancer in The Netherlands. Br. J. Surg. 89, 1142-1149 (2002). (Pubitemid 34989221)
17. Dekker, J. W. et al. Importance of the first postoperative year in the prognosis of elderly colorectal cancer patients. Ann. Surg. Oncol. 18, 1533-1539 (2011).
18. Birgisson, H., Talbäck, M., Gunnarsson, U., Påhlman, L. & Glimelius, B. Improved survival in cancer of the colon and rectum in Sweden. Eur. J. Surg. Oncol. 31, 845-853 (2005). (Pubitemid 41435253)
19. Elferink, M. A. et al. Marked improvements in survival of patients with rectal cancer in the Netherlands following changes in therapy, 1989-2006. Eur. J. Cancer 46, 1421-1429 (2010).
20. Ma, N., Harvey, J., Stewart, J., Andrews, L. & Hill, A. G. The effect of age on the quality of life of patients living with stomas: A pilot study. ANZ J. Surg. 77, 883-885 (2007). (Pubitemid 47353071)
21. Roscio, F. et al. Outcomes of laparoscopic surgery for colorectal cancer in elderly patients. JSLS 15, 315-321 (2011).
22. Mamidanna, R. et al. Reduced risk of medical morbidity and mortality in patients selected for laparoscopic colorectal resection in England: A population-based study. Arch. Surg. 147, 219-227 (2012).
23. Doornebosch, P. G. et al. Transanal endoscopic microsurgery for T1 rectal cancer: Size matters! Surg. Endosc. 26, 551-557 (2012).
24. De Graaf, E. J. et al. Transanal endoscopic microsurgery versus total mesorectal excision of T1 rectal adenocarcinomas with curative intention. Eur. J. Surg. Oncol. 35, 1280-1285 (2009).
25. Habr-Gama, A., Perez, R. O., São Julião, G. P., Proscurshim, I. & Gama-Rodrigues, J. Nonoperative approaches to rectal cancer: A critical evaluation. Semin. Radiat. Oncol. 21, 234-239 (2011).
26. Bokkerink, G. M. et al. The CARTS study: Chemoradiation therapy for rectal cancer in the distal rectum followed by organ-Sparing transanal endoscopic microsurgery. BMC Surg. 11, 34 (2011).
27. Vuong, T., Devic, S. & Podgorsak, E. High dose rate endorectal brachytherapy as a neoadjuvant treatment for patients with resectable rectal cancer. Clin. Oncol. (R. Coll. Radiol.) 19, 701-705 (2007). (Pubitemid 47471495)
28. Meisner, S. et al. Self-Expandable metal stents for relieving malignant colorectal obstruction: Short-Term safety and efficacy within 30 days of stent procedure in 447 patients. Gastrointest. Endosc. 74, 876-884 (2011).
29. Donnellan, F. et al. Efficacy and safety of colonic stenting for malignant disease in the elderly. Int. J. Colorectal Dis. 25, 747-750 (2010).
30. Zbar, A. P., Gravitz, A. & Audisio, R. A. Principles of surgical oncology in the elderly. Clin. Geriatr. Med. 28, 51-71 (2012).
31. Mamidanna, R. et al. Poor 1 year survival in elderly patients undergoing nonelective colorectal resection. Dis. Colon Rectum 55, 788-796 (2012).
32. Tan, C. J., Dasari, B. V. & Gardiner, K. Systematic review and meta-Analysis of randomized clinical trials of self-Expanding metallic stents as a bridge to surgery versus emergency surgery for malignant left-Sided large bowel obstruction. Br. J. Surg. 99, 469-476 (2012).
33. Audisio, R. A. et al. Elective surgery in gastrointestinal tumours in the elderly. Ann. Oncol. 8, 317-326 (1997). (Pubitemid 27230971)
34. Ansaloni, L. et al. Guidelines in the management of obstructing cancer of the left colon: Consensus conference of the world society of emergency surgery (WSES) and peritoneum and surgery (PnS) society. World J. Emerg. Surg. 5, 29 (2010).
35. Jørgensen, T. L., Hallas, J., Friis, S. & Herrstedt, J. Comorbidity in elderly cancer patients in relation to overall and cancer-Specific mortality. Br. J. Cancer 106, 1353-1360 (2012).
36. Pope, D. et al. Pre-Operative assessment of cancer in the elderly (PACE): A comprehensive assessment of underlying characteristics of elderly cancer patients prior to elective surgery. Surg. Oncol. 15, 189-197 (2006). (Pubitemid 46771201)
37. Audisio, R. A., Pope, D., Ramesh, H. S., Gennari, R. & PACE participants. Shall we operate? Preoperative assessment in elderly cancer patients (PACE) can help. A SIOG surgical task force prospective study. Crit. Rev. Oncol. Hematol. 65, 156-163 (2008).
38. Audisio, R. A., Zbar, A. P. & Jaklitsch, M. T. Surgical management of oncogeriatric patients. J. Clin. Oncol. 25, 1924-1929 (2007). (Pubitemid 46854427)
39. Audisio, R. A. & van Leeuwen, B. When reporting on older patients with cancer, frailty information is needed. Ann. Surg. Oncol. 18, 4-5 (2011).
40. Kristjansson, S. R. et al. Comprehensive geriatric assessment can predict complications in elderly patients after elective surgery for colorectal cancer: A prospective observational cohort study. Crit. Rev. Oncol. Hematol. 76, 208-217 (2010).
41. Pawa, N., Cathcart, P. L., Arulampalam, T. H., Tutton, M. G. & Motson, R. W. Enhanced recovery program following colorectal resection in the elderly patient. World J. Surg. 36, 415-423 (2012).
42. American Cancer Society. Cancer Facts & Figures 2011 [online], http://www.cancer.org/acs/groups/content@epidemiologysurveillance/documents/ document/acspc 029771.pdf (2011).
43. Hutchins, L. F., Unger, J. M., Crowley, J. J. Jr & Albain, K. S. Underrepresentation of patients 65 years of age or older in cancer-Treatment trials. N. Engl. J. Med. 341, 2061-2067 (1999). (Pubitemid 30035956)
44. Sargent, D. J. et al. End points for colon cancer adjuvant trials: Observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT group. J. Clin. Oncol. 25, 4569-4574 (2007). (Pubitemid 350035314)
45. UN data. Life expectancy at age x [online], http://data.un.org/Data.aspx? d=GenderStat&f=inID%3A36 (2008).
46. André, T. et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J. Clin. Oncol. 27, 3109-3116 (2009).
47. Kuebler, J. P. et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon: Results from NSABP C 07. J. Clin. Oncol. 25, 2198-2204 (2007). (Pubitemid 46954643)
48. Haller, D. G. et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J. Clin. Oncol. 29, 1465-1471 (2011).
49. Tournigand, C. & de Gramont, A. Is adjuvant chemotherapy an option for stage II colon cancer? Nat. Rev. Clin. Oncol. 8, 574-576 (2011).
50. Moertel, C. G. et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N. Engl. J. Med. 322, 352-358 (1990).
51. Wolmark, N. et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: Results from National Surgical Adjuvant Breast and Bowel project C 04. J. Clin. Oncol. 17, 3553-3559 (1999). (Pubitemid 29517927)
52. André, T. et al. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: Final results of GERCOR C96.1. J. Clin. Oncol. 20, 3732-3738 (2007). (Pubitemid 47372615)
53. Twelves, C. et al. Capecitabine as adjuvant treatment for stage III colon cancer. N. Engl. J. Med. 352, 2696-2704 (2005). (Pubitemid 41007824)
54. Sargent, D. J. et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N. Engl. J. Med. 345, 1091-1097 (2001).
55. Iwashyna, T. J. & Lamont, E. B. Effectiveness of adjuvant fluorouracil in clinical practice: A population-based cohort study of elderly patients with stage III colon cancer. J. Clin. Oncol. 20, 3992-3998 (2002).
56. Jessup, J. M., Stewart, A., Greene, F. L. & Minsky, B. D. Adjuvant chemotherapy for stage III colon cancer: Implications of race/ethnicity, age, and differentiation. JAMA 294, 2703-2711 (2005). (Pubitemid 41770099)
57. Kahn, K. L. et al. Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer. JAMA 303, 1037-1045 (2010).
58. Jackson McCleary, N. A. et al. Impact of older age on the efficacy of newer adjuvant therapies in >12,500 patients with stage II/III colon cancer: Findings from the ACCENT database [abstract]. J. Clin. Oncol. 27 (15 Suppl.), 4010 (2009).
59. Gray, R. et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: A randomised study. Lancet 370, 2020-2029 (2007).
60. Keating, N. L. et al. Adjuvant chemotherapy for stage III colon cancer: Do physicians agree about the importance of patient age and comorbidity? J. Clin. Oncol. 26, 2532-2537 (2008).
61. Van Cutsem, E., Nordlinger, B. & Cervantes, A. on behalf of the ESMO guidelines working group. Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann. Oncol. 21 (SUPPL5), v93-v97 (2010).
62. de Liguori Carino, N. et al. Liver resection for colorectal liver metastases in older patients. Crit. Rev. Oncol. Hematol. 67, 273-278 (2008).
63. Goldberg, R. M. et al. The continuum of care: A paradigm for the management of metastatic colorectal cancer. Oncologist 12, 38-50 (2007). (Pubitemid 46143501)
64. Papamichael, D. et al. Treatment of the elderly colorectal cancer patient: SIOG expert recommendations. Ann. Oncol. 20, 5-16 (2009).
65. Folprecht, G. et al. Efficacy of 5 fluorouracil based chemotherapy in elderly patients with metastatic colorectal cancer: A pooled analysis of clinical trials. Ann. Oncol. 9, 1330-1338 (2004). (Pubitemid 39302467)
66. Popescu, R. A., Norman, A., Ross, P. J. & Cunningham, D. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J. Clin. Oncol. 17, 2412-2418 (1999). (Pubitemid 29368240)
67. Feliu, J. et al. Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: An Oncopaz Cooperative Group Study. J. Clin. Oncol. 23, 3104-3111 (2005). (Pubitemid 46224134)
68. Twelves, C., Hargreaves, D., Nguyen Van Tam, J. & Ng, T. Capecitabine monotherapy in metastatic colorectal cancer. Lancet Oncol. 2, 400 (2001).
69. de Gramont, A. et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 18, 2938-2947 (2000). (Pubitemid 30644117)
70. Tournigand, C. et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J. Clin. Oncol. 22, 229-237 (2004). (Pubitemid 41095086)
71. Cassidy, J. et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J. Clin. Oncol. 26, 2006-2012 (2008).
72. Douillard, J. Y. et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355, 1041-1047 (2000). (Pubitemid 30162806)
73. Mitry, E. et al. Predictive factors of survival in patients with advanced colorectal cancer: An individual data analysis of 602 patients included in irinotecan phase III trials. Ann. Oncol. 15, 1013-1017 (2004). (Pubitemid 39089776)
74. Folprecht, G. et al. Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer. Combined analysis of 2,691 patients in randomized controlled trials. J. Clin. Oncol. 26, 1443-1451 (2008).
75. Goldberg, R. M. et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J. Clin. Oncol. 24, 4085-4091 (2006). (Pubitemid 46622283)
76. Goldberg, R. M. et al. Randomized controlled trial of reduced-Dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: A North American Intergroup Trial. J. Clin. Oncol. 24, 3347-3353 (2006). (Pubitemid 46638888)
77. Seymour, M. T. et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): A randomised controlled trial. Lancet 370, 143-152 (2007). (Pubitemid 47042894)
78. Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342 (2004). (Pubitemid 38702844)
79. Douillard, J. Y. et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J. Clin. Oncol. 28, 4697-4705 (2010).
80. Feliu, J. et al. Capecitabine and bevaccizumab as first-line treatment in elderly patients with metastatic colorectal cancer. Br. J. Cancer 102, 1468-1473 (2010).
81. Price, T. J. et al. Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: A subgroup analysis from the AGITG MAX trial: An international randomized controlled trial of capecitabine, bevacizumab and mitomycin C. Ann. Oncol. 23, 1531-1536 (2012).
82. Sastre, J. et al. First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: Clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study. Oncologist 17, 339-345 (2012).
83. Cassidy, J. et al. Effect of bevacizumab in older patients with metastatic colorectal cancer: Pooled analysis of four randomized studies. J. Cancer Res. Clin. Oncol. 136, 737-743 (2010).
84. Scappaticci, F. A. et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J. Natl Cancer Inst. 99, 1232-1239 (2007). (Pubitemid 47299901)
85. Peeters, K. C. et al. The TME Trial after a median follow-up of 6 years: Increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann. Surg. 246, 693-701 (2007). (Pubitemid 350035641)
86. Sebag-Montefiore, D. et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): A multicentre, randomized trial. Lancet 373, 811-820 (2009).
87. Kozloff, M. et al. Clinical outcomes associated with bevacizumab- containing treatment of metastatic colorectal cancer: The BRiTE observational cohort study. Oncologist 14, 862-870 (2009).
88. Van Cutsem, E. et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: The BEAT study. Ann. Oncol. 20, 1842-1847 (2009).
89. van Gijn, W. et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomized controlled TME trial. Lancet Oncol. 12, 575-582 (2011).
90. Sauer, R. et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N. Engl. J. Med. 351, 1731-1740 (2004).
91. Bosset, J. F. et al. Chemoradiotherapy with preoperative radiotherapy in rectal cancer. N. Engl. J. Med. 355, 1114-1123 (2006).
92. Gérard, J. P. et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3 T4 rectal cancers: Results of FFCD 9203. J. Clin. Oncol. 24, 4620-4625 (2006).
93. Roh, M. S. et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R03. J. Clin. Oncol. 27, 5124-5130 (2009).
94. Paun, B. C., Cassie, S., MacLean, A. R., Dixon, E. & Buie, W. D. Postoperative complications following surgery for rectal cancer. Ann. Surg. 251, 807-818 (2010).
95. Borowski, D. W. et al. Volume-Outcome analysis of colorectal cancer-Related outcomes. Br. J. Surg. 97, 1416-1430 (2010).
96. Jung, B., Påhlman, L., Johansson, R. & Nilsson, E. Rectal cancer treatment and outcome in the elderly: An audit based on the Swedish Rectal Cancer Registry 1995-2004. BMC Cancer 9, 68 (2009).
97. Quipourt, V., Jooste, V., Cottet, V., Faivre, J. & Bouvier, A. M. Comorbidities alone do not explain the undertreatment of colorectal cancer in older adults: A French population-based study. J. Am. Geriatr. Soc. 59, 694-698 (2011).
98. Pignon, T. et al. Age is not a limiting factor for radical radiotherapy in pelvic malignancies. Radiother. Oncol. 42, 107-120 (1997). (Pubitemid 27132740)
99. Larsen, S. G., Wiig, J. N., Tretli, S. & Giercksky, K. E. Surgery and pre-Operative irradiation for locally advanced or recurrent rectal cancer in patients over 75 years of age. Colorectal Dis. 8, 177-185 (2006). (Pubitemid 43379501)
100. Martijn, H. & Vulto, J. C. Should radiotherapy be avoided or delivered differently in elderly patients with rectal cancer? Eur. J. Cancer 43, 2301-2306 (2007). (Pubitemid 47539118)